The Texas medication algorithm project: Report of the Texas consensus conference panel on medication treatment of major depressive disorder

Journal of Clinical Psychiatry

Volumn 60, Issue 3, 1999, Pages 142-156

  Crismon, M Lynn ^a   Trivedi, Madhukar ^b   Pigott, Teresa A ^c   Rush, A John ^b   Hirschfeld, Robert M A ^c   Kahn, David A ^d   DeBattista, Charles ^f   Nelson, J Craig ^g   Nierenberg, Andrew A ^h   Sackeim, Harold A ^e   Thase, Michael E ⁱ  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d Columbia University ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZATROPINE; BUSPIRONE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; DEPRESSION; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; ELECTROCONVULSIVE THERAPY; HEALTH CARE PLANNING; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032901376     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0302     Document Type: Article

References (28)

1. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351
2. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville. Md: US Dept Health Human Services. Agency for Health Care Policy and Research; April 1993. AHCPR publication 93-0551
3. Rush AJ, Prien RF. From scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged? Psychopharmacol Bull 1995;31:7-20
4. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatments of Psychiatric Disorders, vol 1. 2nd ed. Washington, DC: American Psychiatric Press; 1995:1349-1368
5. Sobin C, Prudic J, Devanand DP, et al. Who responds to electroconvulsive therapy? a comparison of effective and ineffective forms of treatment. Br J Psychiatry 1996;169:322-328
6. Prudic J, Sackeim HA, Ritas S. Medication resistance, response to ECT, and prevention of relapse. Psychiatr Ann 1994;24:228-231
7. Nierenberg AA, McLean NE, Alpert JA, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152: 1500-1503
8. Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother. In press
9. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press: 1995:1081-1097
10. Still DJ, Crismon ML. Pharmacoeconomics of depression. Clin Pharm Newswatch 1995;2(11):1-6
11. Fava M, Rosenbaum JF. Pharmacotherapy and somatic therapies. In: Beckham EE, Leber WR, eds. Handbook of Depression. New York, NY: Guilford Publications; 1995:280-301
12. DeBattista C, Belanoff J, Schatzberg AF. Treatment of psychotic depression. In: Montgomery S, Halbreich U, eds. Hormones, Brain, and Neuropsychopharmacology, Book 4: Pharmacotherapy of Mood and Cognition. Washington, DC: American Psychiatric Press. In press
13. Nelson JC. Augmentation strategies for treatment of unipolar major depression. Mod Probl Pharmacopsychiatry 1997;25:34-55
14. American Psychiatric Association. Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993;150(4, suppl):S1-S26
15. Jobson KO, Potter WZ. International psychopharmacology algorithm project report. Psychopharmacol Bull 1995;31:457-459
16. Rush AJ, Clinical practice guidelines: good news, bad news, or no news? Arch Gen Psychiatry 1993;50:483-490
17. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902
18. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. Am J Managed Care 1996;2:253-264
19. Lomas J. Words without action? the production, dissemination, and impact of consensus recommendations. Annu Rev Public Health 1991;12:41-65
20. Dotson LR, Witmer DR. Development of ASHP therapeutic guidelines. Am J Health Syst Pharm 1995;52:254-255
21. Field JF, Lohr KN, eds. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academic Press; 1990
22. Rey JA, Crismon ML, Dopheide JA, et al. Management of major depression in adults. In: Manolakis P, ed. APhA Guide to Drug Treatment Protocols: A Resource for Creating and Using Disease Specific Pathways. Washington, DC: American Pharmaceutical Association; 1997: MD-i-MD-11
23. Nelson JC, Docherty JP, Henschen GM, et al. C. Algorithms for the treatment of subtypes of unipolar major depression. Psychopharmacol Bull 1995;31:475-482
24. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995;52:2799-2812
25. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29(suppl 1):10-18
26. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55(12, suppl):3-15
27. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995;7:143-147
28. Cohen LJ. Rational drug use in the treatment of depression. Pharmacotherapy 1997;17:45-61